1. Home
  2. KLAC vs NVO Comparison

KLAC vs NVO Comparison

Compare KLAC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KLA Corporation

KLAC

KLA Corporation

N/A

Current Price

$1,452.53

Market Cap

187.4B

Sector

Technology

ML Signal

N/A

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

N/A

Current Price

$38.67

Market Cap

269.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KLAC
NVO
Founded
1975
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.4B
269.6B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
KLAC
NVO
Price
$1,452.53
$38.67
Analyst Decision
Buy
Hold
Analyst Count
19
11
Target Price
$1,643.11
$51.00
AVG Volume (30 Days)
756.1K
19.0M
Earning Date
04-30-2026
01-01-0001
Dividend Yield
0.52%
3.18%
EPS Growth
49.75
N/A
EPS
17.15
N/A
Revenue
N/A
N/A
Revenue This Year
$12.32
N/A
Revenue Next Year
$19.94
$3.30
P/E Ratio
$84.28
$13.60
Revenue Growth
N/A
N/A
52 Week Low
$551.33
$35.85
52 Week High
$1,693.35
$82.23

Technical Indicators

Market Signals
Indicator
KLAC
NVO
Relative Strength Index (RSI) 49.93 33.90
Support Level $852.48 $35.85
Resistance Level $1,579.34 $50.30
Average True Range (ATR) 56.56 0.88
MACD -11.65 0.16
Stochastic Oscillator 50.37 22.45

Price Performance

Historical Comparison
KLAC
NVO

About KLAC KLA Corporation

KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: